A single dose of an siRNA molecule reduces elevated lipoprotein(a) — a major, but to date, largely untreatable risk factor ...

Food additive mixtures commonly found in diet drinks, soups, dairy desserts and sauces may slightly increase a person's risk ...

A new drug in clinical trials is showing promise in lowering a key genetic risk factor for heart attacks and ...

Eli Lilly (NYSE:LLY) has recently announced several developments, including positive Phase 2 results for their siRNA therapy ...

Strokes caused by an artery tear are landing five times as many Americans in the hospital these days, a new study says.

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...

Novo Nordisk is licensing a drug called LX9851 from Lexicon Pharmaceuticals for up to $75 million in upfront and near-term ...

A dose of an experimental drug reduced the levels of a fatal type of cholesterol for up to a year despite previous knowledge that it's untreatable. NBC News reported that pharmaceutical company Eli ...